A recent study indicates that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds far faster than those who halt traditional diet and exercise programs.
Published data in a leading health publication points out that while obese people can lose substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using such treatments should be informed of the risk of rapid rebound weight gain when the medication ends," stated lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to original mass in about 18 months.
Weighing Treatments
The study, which reviewed 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through lifestyle changes alone typically see a slower creep back—approximately 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Experts propose the mechanism of the injections explains the heightened regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in appetite is unsuppressed, making excessive eating a significant risk."
A Chronic Disease?
Health authorities advise the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the likelihood of weight regain, the treatment should be considered life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the long-term character of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
Users who have stopped the jabs describe a powerful resurgence of hunger.
"I experienced something that goes on and I was suddenly ravenous," described an individual.
This challenge is compounded if patients have not established sustainable lifestyle or habit changes during therapy.
Significant Use
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is more common among women than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while the jabs are powerful agents for shedding pounds, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural changes.
